Wednesday 17 March

WelcomeJean-Pierre Pouget - Institut de Recherche en Cancérologie de Montpellier, France
Chairs: Bart Cornelissen, Danny Feijtel
14:00Invited live lecture:
MRT in neuroendocrine tumours: role of radiobiology(20+10 min)
Emmanuel Deshayes, ICM Montpellier, France
Live talks:
14:30Target heterogeneity in models for peptide receptor radionuclide therapy influences therapeutic response (10min + 5min)
Danny Feijtel, Erasmus MC, Netherland
14:45Auger electrons for molecular radionuclide therapy: the potential of the radionuclide technetium-99m (10min + 5min)
Inès Costa, King's College of London, United-Kingdom
15:00High-throughput screening and bioinformatics analysis of 2,000177Lu-PSMA and Radiotherapy + drug combinations (10min + 5min)
Tiffany Chan, University of Oxford, United-Kingdom
15:15α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [223Ra]RaCl2-treated prostate cancer patients (10min + 5min)
Uta Eberlein, University of Wurzburg, Germany
15:30 Break (15min)
Chairs: Samantha Terry, Sophie Poty
15:45Invited live lecture on the therapy of micrometastasis and residual disease:
Choice of the radionuclide and target in the therapy of metastatic and residual disease: needs in radiobiology (20+10 min)
Elif Hindie, CHU Bordeaux, France
16:15Presentation and discussion around the future work of the MRT Radiobiology working group (30min)
Jean-Pierre Pouget, Bart Cornelissen, Julie Nonnekens, Samantha Terry and all attendees
16:45Surprising presentation of Montpellier’s way of life! (5min)
16:50Teaser for the Thursday’s “for and against” debate (1min)
16:51Summary of the day
Jean-Pierre Pouget, Bart Cornelissen

Thursday 18 March

Chairs: Manuel Bardiès, Marta Cremonesi
10:00Invited live lecture:
Dose-effect relationship in clinical MRT: a place for radiobiology? (20+10 min)
Mark W. Konijnenberg, Erasmus MC Rotterdam, Netherlands
Chair: Julie Nonnekens
10:30Entertaining and passionate debate followed by one final vote of participants (30min)
This house believes that radiobiology is useful for improving MRT?

For: Frederik Verburg (Nucl. Med. Physician, Erasmus MC Rotterdam Netherlands)
Against: Christophe Badie (Radiobiologist, Public Health England Oxfordshire, United-Kingdom)
Chairs: Bart Cornelissen, Jean-Pierre Pouget
11:00Round tables: What are the immediate clinical questions in MRT? (45min)
Participants: Emmanuel Deshayes (ICM, Montpellier, France), Elif Hindie (CHU Bordeaux, France), Katherine Vallis (University of Oxford, United-Kingdom), M. Gaze (University College London Hospitals NHS Foundation Trust, United-Kingdom)
11:45 Break (15min)
Chairs: Bart Cornelissen, Samantha Terry
12:00 Round table about the future work of the MRT Radiobiology working group (45min)
Participants: all
Expert view: Kevin Prise
Expert view: Simon Bouffler
12:45 Lunchbreak
13:15Sponsors’ time
  • Molecubes – Katarzyna Desrocques
  • MILabs - Freek Beekman
  • SCK CEN - Geerts Joris
Chairs: Christophe Badie, Édouard Azzam
14:00Invited live lecture:
Low dose and low dose rate radiobiology of MRT (20+10 min)
Eva Forssell-Aronsson, University of Gothenburg, Sweden
14:30E-posters: 8 preselected abstracts (5 min) +Q/A at the end for all (5 min)
Therapeutic investigation of Auger electron emitter 67Ga-DOTA-PSMA and 67Ga (5 min)
Élise Verger, King’s College London, London, United-Kingdom
Potentiation of targeted radionuclide therapy using gadolinium-based nanoparticles (5 min)
Clara Diaz Garcia-Prada, Institut de Recherche en Cancérologie de Montpellier, France
Extensive preclinical evaluation of Lutetium-177 labeled PSMA-specific tracers for prostate cancer radioligand therapy (5 min)
Eline Ruigrok, Erasmus MC, Rotterdam, The Netherlands
Multicellular prostate tumor spheroids for evaluation of the therapeutic potential of copper-64 (5 min)
Catarino Pinto, Instituto Superior Técnico, Universidade de Lisboa
DNA Damage response speed imaging predicts is survival following Lutetium-177 radionuclide therapy in vivo (5 min)
Edward O'Neill, University of Oxford, Oxford, United-Kingdom
Dosimetry at the cellular level: measuring reactive oxygen species induced by ionizing radiation (5 min)
Eero Hippeläinen, University of Helsinki and Helsinki University Hospital, Finland
Role of small extracellular vesicles in the non-targeted bystander effects of targeted radiotherapy (5 min)
Jihad Karam, Institut de Recherche en Cancérologie de Montpellier, France
Relating DNA damaging effects of radionuclides to those from external beam radiotherapy (5 min)
Elise Verger, King’s College London, London, United-Kingdom
15:15 Break (15min)
Chairs: Sandra Heskamp, Julie Constanzo
Live talks:
15:30Molecular response of head and neck squamous cell carcinoma (HNSCC) upon a combination treatment with molecular- and external radiotherapy (10 min + 5 min)
Treewut Rassamegevanon, National Center for Radiation Research in Oncology, Germany
15:45P53-mediated radiosensitization of 177Lu-DOTATATE treatment in neuroblastoma tumor spheroids (10 min + 5 min)
Sara Lundsten, Uppsala University, Sweden
16:00Reversing cold tumor microenvironment with targeted alpha-therapy (10 min + 5 min)
Justine Perrin, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, France
16:15Cytosolic dsDNA and extracellular vesicles participate to antitumor immunity induced by external and targeted radiotherapy (10 min + 5 min)
Julie Constanzo, Institut de Recherche en Cancérologie de Montpellier, France
16:30Invited live lecture
Radiation oncology and immunology (20 + 10 min)
Claire Vanpouille-Box, Weill Cornell Medicine, New-York, USA
17:00Awards ceremony + summary
17:30 End of workshop by Jean-Pierre Pouget

In partnership with